Boston Scientific Corp. Stock Hits New 52-Week Low at USD 46.91

Boston Scientific Corp. has reached a significant milestone by touching a new 52-week low of USD 46.91 on June 11, 2026. This marks a notable decline in the stock's performance, with a one-year decrease of 39.07%, contrasting sharply with the S&P 500's gain of 22.78% during the same period. The company operates within the retailing industry and boasts a market capitalization of approximately USD 120.85 billion, categorizing it as a large-cap entity. Financial metrics reveal a price-to-earnings (P/E) ratio of 36.00, indicating the market's valuation of the company's earnings. Additionally, Boston Scientific has a debt-to-equity ratio of 0.39, suggesting a relatively low level of debt compared to its equity. The return on equity stands at 13.88%, reflecting the company's efficiency in generating profits from shareholders' equity. Despite the current stock price challenges, Boston Scientific's fundamentals provide a comprehensive view of its market position and financial health within the retailing sector.